Domain Therapeutics has announced the appointment of Dr Jean-Marie Cuillerot as Chief Medical Officer (CMO). Dr Cuillerot brings pharmaceutical and biotech experience, with a track record in leading successful clinical development programmes and regulatory strategy. Earlier in his career, Dr Cuillerot served as the… Read More
The first patients have been dosed in a Phase I/II trial of Domain Therapeutics’ DT-7012 targeting CCR8 in solid cancer tumours DT-7012 is a novel immunotherapy candidate designed to selectively deplete intra-tumoural regulatory T cells (Tregs) by targeting CCR8, a receptor predominantly expressed… Read More
Domain Therapeutics has announced plans to progress DT-9046, a candidate it says has game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine. PAR2 has emerged as a pivotal therapeutic in inflammatory diseases due to its… Read More
